Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD8586 in Relapsed or Refractory DLBCL
NCT06539195Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Mar 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of birelentinib in diffuse large B-cell lymphoma (DLBCL) (3 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoint: Objective Response Rate up to 2 years. Started Mar 2024; status: completed.
02
Drugs
birelentinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06539195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06539195.